Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
First Quarter Results
On May 10, SABESP reported upbeat first quarter 2012 results with earnings per share of R$2.16 ($2.20 per ADR), marking a gain from R$0.80 in the year-ago quarter. The result surpassed the Zacks Consensus Estimate of $1.62 per ADR.
Net sales grew 12.8%, primarily due to a 3.0% rise in billed water and sewage volumes. The number of connections and consumption grew well in the quarter. Operating margin expanded 880 basis points to 27.5% on the back of rising revenues and declining operating expenses.
Also, in an effort to improve capacity, SABESP announced investment plans worth R$7.9 billion for the 2012-2015 period. The company emphasizes increasing its water supply coverage, implementing a 3% hike in sewage collection to 85% and increasing collected sewage treatment to 83% from 76%.
Estimates Moving Higher
In the last 60 days, the Zacks Consensus Estimate for 2012 inched up 1.4% to $7.43 per ADR, while 2013 remained stable at $7.50 per ADR. These estimates reflect year-over-year growth of 25.85% for 2012 and 1.01% for 2013.
A Value Play
The chart below clearly shows that the stock has traveled a long way from $40 to $80 per share in the last two years. It plunged in the second half of 2011, but recovered quickly in the beginning of 2012.
In addition to a low P/B, SABESP is currently trading at a forward P/E multiple of 10.65, compared with the peer group average of 18.42. A P/E below 15.0 and a P/B ratio under 3.0 generally indicate value.
SABESP is based in the State of São Paulo, Brazil, and was founded in 1954. Serving roughly 23.9 million water and 20.5 million sewage customers, the company is the fifth largest sanitation company in the world. SABESPs principal shareholder is the São Paulo government, which owns nearly 50.3% of the company.
Get the full Analyst Report on SBS - FREE